5MPN (C007B-374811)

5MPN is a first-in-class, potent, orally active and selective 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 ( PFKFB4 ) inhibitor. 5MPN appears to be a competitive inhibitor of the F6P binding site ( K i =8.6 μM). 5MPN does not inhibit PFK-1 or PFKFB3. 5MPN targets the sugar metabolism of tumors and suppresses proliferation of multiple human cancer cell linesIn Vitro5MPN (0~30 μM; 24 hours; H460 cells) inhibits the expression of PFKFB4. 5MPN (0~50 μM; 0~72 hours; H460 NSCLC cells) first reduces the intracellular concentration of F2,6BP, glycolysis and ATP, which in turn results in a reduction in cell proliferation. 5MPN (0 and 10 μM; 6, 12 and 24 hours; H460 cells) induces cells apoptosis. 5MPN (0 and 10 μM; 6, 12 and 24 hours; H460 cells) arrests cell cycle progression. 5MPN (0.1, 1 or 10 µM) significantly inhibits PFKFB4 activity. 5MPN (H460 cells) leads to a dose-dependent decrease in the intracellular F2,6BP concentration. 5MPN (0~30 μM; over 48 hours; H460, H1299, H441, H522 and A549 cells) makes a dose-dependent reduction in cells growth. 5MPN (0~30 μM; 24 hours; H460 cells) inhibits PFKFB4 expression causing the observed reduction in H460 cell proliferation. 5MPN causes a G1 arrest in LLC cells in vitro similar to H460 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: H460 cells Concentration: 0~30 μΜ Incubation Time: 24 hours Result: Inhibited the expression of PFKFB4 . Cell Proliferation AssayCell Line: H460 NSCLC cells Concentration: 0~50 μM Incubation Time: 0~72 hours Result: Resulted in a reduction in cell proliferation. Apoptosis AnalysisCell Line: H460 cells Concentration: 0 and 10 μΜ Incubation Time: 6, 12 and 24 hours Result: Induced cells apoptosis. Cell Cycle AnalysisCell Line: H460 cells Concentration: 0 and 10 μΜ Incubation Time: 6, 12 and 24 hours Result: Arrested cell cycle progression.In Vivo5MPN (120 mg/kg; p.o.) suppresses the growth of Lewis lung carcinomas (LLC) grown in syngeneic mice and H460 human lung adenocarcinoma xenografts grown in athymic mice without affecting body weight . 5MPN causes a reduction in Ki67-positive cells in the LLC xenografts suggesting that 5MPN may be reducing cell cycle progression in vivo . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6 mice Dosage: 120 mg/kg Administration: P.o. Result: Suppressed the growth of Lewis lung carcinomas (LLC) grown in syngeneic mice and H460 human lung adenocarcinoma xenografts grown in athymic mice without affecting body weight.Form:SolidIC50& Target:KI: 8.6 μM (PFKFB4). Specification: ≥98.0% Molecular Formula: C15H19N3O4 Molecular Weight: 305.33 PubChem CID: 4060327 Isomeric SMILES: COC1=CC=CC2=C(C=CN=C21)NCCCCCO[N+](=O)[O-]

UPC:

12352200

Condition:

New

Weight:

1.06 Ounces

HazmatClass:

No

Quantity:

1

Unit of Measurement:

EA

WeightUOM:

LB

MPN:

M649540-50mg

CAS:

47208-82-2

Product Size:

50mg